{"disease":{"id":"bipolar-affective-disorder","name":"bipolar affective disorder"},"drugs":{"marketed":[{"drug_id":"cariprazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"aripiprazole","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"fluoxetine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"sodium valproate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"asenapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"carbamazepine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"risperidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"carbamazepin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"valproic-acid","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"prozac","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"lithium","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lithium-carbonate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lurasidone","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"doxepin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abilify","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"lithium-citrate","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":10,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode manic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05480150","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07129408","title":"Epidemiological Study on the Prevalence of Mental Disorders in Slovakia","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"Comenius University","has_results":false},{"nct_id":"NCT06657430","title":"A Study on the Preference of Risperidone Dosage Forms","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT05658510","title":"Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":false},{"nct_id":"NCT03240380","title":"Joint Crisis Plans or Crisis Cards for People With Severe Mental Disorders to Reduce Coercion in Psychiatric Care.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":374,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT05030272","title":"Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings","phase":"NA","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT06831435","title":"Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":325,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06740383","title":"Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services","phase":"","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT06033326","title":"Validation of the French Version of the Lithium Knowledge Test (LKT)","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03050853","title":"The Appeal and Impact of E-cigarettes in Smokers With SMI","phase":"NA","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT05725785","title":"Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06758414","title":"CBT-CP for Veterans With SMI","phase":"NA","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT04298450","title":"ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention","phase":"NA","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Centre for Addiction and Mental Health","has_results":false},{"nct_id":"NCT06978465","title":"DIALOG: Understanding Disorganisation: A Language-focused Global Initiative in Psychosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Douglas Mental Health University Institute","has_results":false},{"nct_id":"NCT02453217","title":"The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Wai-Tong Chien","has_results":false},{"nct_id":"NCT04004416","title":"Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT06182787","title":"Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient","phase":"","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT05915312","title":"Exosome for Early Diagnosis of Bipolar Affective Disorder","phase":"","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Tianjin Anding Hospital","has_results":false},{"nct_id":"NCT03925038","title":"Electronic Communication Augmented Mental Health Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT07398365","title":"Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT07213466","title":"Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03919760","title":"Early Psychosis Intervention - Spreading Evidence-based Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Centre for Addiction and Mental Health","has_results":false},{"nct_id":"NCT05249309","title":"Naturalistic Study of Ketamine in the Treatment of Depression","phase":"","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT05406414","title":"The Efficacy of a Transdiagnostic Sleep and Circadian Intervention for Patients With Mental Disorders and Sleep Problems","phase":"NA","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05023252","title":"Mobile Self-Tracking of Mental Health","phase":"NA","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT06911931","title":"Visual Perception in Schizophrenia","phase":"NA","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT00202293","title":"Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Melbourne Health","has_results":false},{"nct_id":"NCT06904079","title":"Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents","phase":"NA","overall_status":"RECRUITING","enrollment_count":82,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT06743711","title":"Validation and Impact of Cardiorespiratory Fitness in Severe Mental Illness - the Heart in Mind Project","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Bjorn H. Ebdrup","has_results":false},{"nct_id":"NCT05064319","title":"Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT07463911","title":"Treatment Response In ECT Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Nurdan Sağbaş","has_results":false},{"nct_id":"NCT05945277","title":"Critical Time Intervention-Peer Support","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Lisbon Institute of Global Mental Health - LIGMH","has_results":false},{"nct_id":"NCT04222816","title":"Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"All India Institute of Medical Sciences, Bhubaneswar","has_results":false},{"nct_id":"NCT06176456","title":"Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Moscow Psychiatric Hospital No. 1 Named after N.A. Alexeev","has_results":false},{"nct_id":"NCT04526067","title":"In-person vs. Remote Wellness Support","phase":"NA","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"The University of Texas Health Science Center at San Antonio","has_results":true},{"nct_id":"NCT01244854","title":"Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05340686","title":"Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression","phase":"NA","overall_status":"SUSPENDED","enrollment_count":54,"lead_sponsor_name":"Region Stockholm","has_results":false},{"nct_id":"NCT06558201","title":"Open Label Extension Study of NCT06221852","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Mclean Hospital","has_results":false},{"nct_id":"NCT06221852","title":"Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mclean Hospital","has_results":false},{"nct_id":"NCT03275714","title":"Evaluation of an App for Smartphones for People With a Bipolar Affective Disorder","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT04118283","title":"Assessment and Treatment for Chronic Pain in Veterans With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT04011280","title":"Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"University of California, San Diego","has_results":true},{"nct_id":"NCT03310593","title":"Cannabidiol as an Adjunctive Treatment for Bipolar Depression","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT07116694","title":"Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":false},{"nct_id":"NCT05098353","title":"Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Federal Stare Budgetary Scientific Institution, Mental Health Research Center","has_results":false},{"nct_id":"NCT06131268","title":"The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT03249857","title":"Study of Sensorimotor Compatibility Effects in Bipolar Affective Disorder.","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT06041646","title":"Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":true},{"nct_id":"NCT03208036","title":"Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT04168697","title":"Effect of Behavioral Intervention on Cannabinoid Receptors in BAD","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Wayne State University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}